Angeion gets defibrillator study approval:
This article was originally published in Clinica
Angeion has been granted an investigational device exemption for its Sentinel 2010 implantable cardioverter defibrillator system. The company recently received FDA permission to expand its trial of the Sentinel 200 to 25 sites. Both devices have CE marking in the European Union. The 2010 is the first Angeion defibrillator to store ECG data and has enhanced programming features.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.